Perrigo Company plc - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on March 1, 2021, by Perrigo Company plc (PRGO). The filing discloses the entry into a Material Definitive Agreement regarding the sale of a major business segment.
Key Financial Metrics and Transaction Details
The filing details a Stock and Asset Purchase Agreement with Vestas Pharma LLC, an affiliate of Altaris Capital Partners. Key financial terms include:
- Total Consideration: $1.55 billion, subject to customary adjustments for cash, debt, working capital, and transaction expenses.
- Cash Component: $1.5 billion.
- Contingent Obligations: Buyer assumes approximately $55 million in potential R&D milestone payments and contingent purchase obligations related to third-party Rx partners.
- Termination Fee: A Reverse Termination Fee of $90 million in cash is payable by the Buyer if the agreement is terminated due to Buyer's breach or failure to consummate the transaction under certain circumstances.
Material Changes and Transaction Structure
The transaction involves the sale of Perrigo's Generic Rx Pharmaceuticals business. The agreement includes specific provisions regarding liabilities:
- Perrigo will retain a portion of liabilities arising from pre-closing antitrust and opioid matters, as well as the Albuterol recall, subject to limitations.
- Representations and warranties do not survive closing; pre-closing covenants survive for 9 months.
- Financing for the transaction includes equity and debt commitments obtained by the Buyer.
Outlook, Risks, and Contingencies
Closing Timeline: The Company expects to close the transaction by the end of the third quarter of fiscal year 2021. The "Outside Date" for closing is September 1, 2021, with automatic extensions to December 1, 2021, and March 1, 2022, if antitrust conditions are not met but other conditions are satisfied.
Conditions Precedent: Closing is subject to the termination of the Hart-Scott-Rodino waiting period, absence of laws preventing closing, and no "Business Material Adverse Effect."
Risks: Forward-looking statements highlight risks regarding the ability to achieve expected benefits, failure to obtain regulatory approvals, and potential costs or liabilities exceeding estimates. The filing includes a standard disclaimer that the Company has no obligation to update forward-looking statements.
Investor Verification Checklist
- Verify the final closing date and whether the transaction closes within the expected Q3 2021 timeframe.
- Monitor the status of antitrust approvals and the Hart-Scott-Rodino waiting period.
- Review the final purchase price adjustments related to cash, debt, and working capital at closing.
- Assess the impact of retained liabilities (antitrust, opioid, Albuterol recall) on future financial statements.
- Confirm the Buyer's financing commitments remain intact and unencumbered.